EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE


facebook twitter youtube
News archive
Recent news

 

Along with CAR-T cell treatment, bispecific antibodies has been one of the most important topics discussed at the American Society (ASH) Annual Meeting. This family of drugs has shown very promising results in early phases of clinical trials in heavily pre-treated myeloma patients. Dr Mohamad Mohty, Head of Haematology and and Celular Therapy Department, Saint-Antoine Hospital and University Pierre & Marie Curie, Paris, France, summarises for Myeloma Patients Europe (MPE) the most important updates on bispecific antibodies at ASH 2019.

 

 







Recent news

» Watch the webinar on ASH 2020 myeloma and AL amyloidosis highlights

» ASH 2020 AL amyloidosis highlights

Leave a Reply

Your email address will not be published. Required fields are marked *

I accept the Privacy Policy * for Click to select the duration you give consent until.